Until 2010 it was marketed and prescribed as an adjunct in the treatment of exogenous obesity along with diet and exercise.
It has been associated with increased cardiovascular events and strokes and has been withdrawn from the market in countries and regions including Australia, Canada, China, the European Union (EU), Hong Kong, India, Mexico, Thailand, the UK, and the United States.
Sibutramine is a centrally-acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines, although its mechanism of action is distinct.
Sibutramine was originally developed and marketed by Knoll Pharmaceuticals and was most recently manufactured and marketed by Abbott Laboratories before its withdrawal from the market.
It was sold under a variety of brand names including Reductil, Meridia and Sibutrex.
It is classified as a Schedule IV controlled substance in the United States.
More on Sibutramine
STUDY QUESTIONS
- What is Sibutramine?
- What is the structure of Sibutramine?
- How does Sibutramine function?
- What is Sibutramine used for?
- Is Sibutramine a hazardous/harmful substance to human health?
- What are the adverse effects of Sibutramine?
- What conditions are connected/attributed to Sibutramine?
- Which countries have banned Sibutramine?
- Is Sibutramine allowed/disallowed in Malaysia?
- Has Malaysia banned Sibutramine?
- What are the products available in Malaysia that contain Sibustramine?
- Is public awareness about Sibutramine sufficient to protect them against its harm?
0 comments:
Post a Comment